Valion Bio (VBIO) Total Liabilities (2021 - 2026)

Valion Bio has reported Total Liabilities for 6 years, with the latest figure at $20.6 million in Q2 2026.

• On a quarterly basis, Total Liabilities rose 2407.67% year-over-year to $20.6 million in Q2 2026; TTM through Jun 2026 was $20.6 million, a 2407.67% increase from a year earlier, with the FY2025 full-year figure at $7.4 million, up 2635.29% from the prior year.
• Total Liabilities was $20.6 million for Q2 2026 at Valion Bio, up from $7.4 million in the prior quarter.
• The five-year high for Total Liabilities was $20.6 million in Q2 2026, with the low at $272000.0 in Q4 2024.
• Average Total Liabilities over 5 years is $2.8 million, with a median of $1.4 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities slumped 82.75% in 2024, then soared 2635.29% in 2025.
• Over 5 years, Total Liabilities stood at $2.2 million in 2022, then retreated by 29.76% to $1.6 million in 2023, then plunged by 82.75% to $272000.0 in 2024, then jumped by 2635.29% to $7.4 million in 2025, then jumped by 176.72% to $20.6 million in 2026.
• The last three Total Liabilities figures came in at $20.6 million (Q2 2026), $7.4 million (Q4 2025), and $638000.0 (Q3 2025), per Business Quant data.